ClinicalTrials.gg
RecruitingNCT02038660IRIS DEBUpdated Dec 29, 2025

Drug-Eluting Balloon Registry in Routine Clinical Practice

An observational study in Coronary Artery Disease and Angioplasty, Balloon, sponsored by Seung-Jung Park. Recruiting at 9 sites in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Seung-Jung Park · Observational

How we know

From the registry’s dates

  • Started Jan 2014; still recruiting 12 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Coronary Artery Disease by Seung-Jung Park — 11 open to participants now, 13 under way, none of them phase 3. Coronary Artery Disease · Seung-Jung Park.

Planned enrollment
18th of 30
1,500 · median 2,000
Started
2014
with 6 others
Observational
30 of 59
10 open now
Primary completion
2026-12
later than 2 of 12 live
Registered
40th of 59
by date

Among the 59 studies in Coronary Artery Disease by Seung-Jung Park, this one is the 18th largest by planned enrollment of the 30 observational ones that give a count, is one of 7 that started in 2014, is one of 30 observational ones, reaches primary completion later than 2 of the 12 other live ones, and was the 40th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

11 of the 59 studies in Coronary Artery Disease by Seung-Jung Park are open now, in 8 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Coronary Artery Disease by Seung-Jung Park, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate long-term effectiveness and safety of patients with coronary disease treated with drug eluting balloon in real world practice.

03

Conditions studied

  • Coronary Artery Disease
  • Angioplasty, Balloon

Keywords

  • Coronary Artery Disease
  • Angioplasty, Balloon
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients treated with balloon angioplasty

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • After pre dilatation residual stenosis 30% and less and also without vessel dissection interrupted blood flow
  • Age 20 and more
  • Treated with Balloon angioplasty
  • Signed and agreed to follow protocol

Exclusion criteria

Exclusion Criteria:

  • Allergy to paclitaxel, antiplatelet
  • History of side effect to heparin, aspirin, thienopyridines
  • History of bleeding tendency, coagulation disorder, blood transfusion reaction
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with coronary artery disease

    Device: Balloon angioplasty

Interventions

  • DeviceBalloon angioplasty
06

What researchers measure

Primary outcomes

  1. Composite Event

    Death, Non-fatal myocardial infarction, Target vessel revascularization

    Time frame: 1year

Secondary outcomes

  1. All cause death

    Time frame: 5year

  2. Cardiac death

    Time frame: 5year

  3. Myocardial infarction

    Time frame: 5year

  4. Composite event

    Death or myocardial infarction

    Time frame: 5year

  5. Composite event

    Cardiac death or myocardial infarction

    Time frame: 5year

  6. Target vessel revascularization

    Time frame: 5year

  7. Target lesion revascularization

    Time frame: 5year

  8. Stent thrombosis

    Classification of stent thrombosis according to Academic Research Consortium criteria

    Time frame: 5year

  9. Stroke

    Time frame: 5year

  10. Procedural Success

    Defined as less than 30% residual stenosis at the completion of procedure without death or Q wave myocardial infarction or urgent revascularization. Participants will be followed for the duration of hospital stay, an expected average of 3days.

    Time frame: 3day

07

Study locations

6 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — This is not a publicly funded trial.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2014 (actual). Primary completion is estimated for Dec 2026, 155 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 155 months is above that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2014
First posted
Jan 16, 2014
StartActual
Jan 2014
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 2027
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02038660
Lead sponsor
Seung-Jung Park
Collaborators
CardioVascular Research Foundation, Korea, B. Braun Korea Co., Ltd.
Responsible party
Seung-Jung Park (MD,PhD, Asan Medical Center) — Sponsor-investigator
First posted
Jan 16, 2014
Start date
Jan 2014
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Dec 29, 2025

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion